Specialty Chemicals company Epigral announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Revenue stood at Rs 632 crore, growth of 32% YoY on account of volume growth from Derivative products. Revenue contribution from Derivatives & Specialty business increased to 59% in Q2FY25 vs 46% in Q2FY24. EBITDA stood at Rs 178 crore vs Rs 108 crore in Q2FY24, grew by 65% YoY. EBIDTA margin stood at 29% in Q2FY25 vs 23% in Q2FY24 on account of increase in utilization and volume contribution from new projects commissioned. PAT grew by 111% to Rs 81 crore. PAT margin grew to 13% vs 8% in Q2FY24. ROCE grew to 24% as on 30th September 2024 vs 21% as on Q2FY24. Net Debt / EBITDA reduced to 1.4x as on 30th September 2024 vs 1.8x as on Q2FY24. Q2FY25 Operational Highlights: Sales volume grew 6% YoY, it majorly comes from Derivatives and Specialty business. Capacity utilization stood at 83% in Q2FY25 vs 77% in Q2FY24. YoY realizations dropped for all the products in range of 1% to 7%, except for Chloromethanes. Caustic Soda realization dropped by 9% QoQ. Realization marginally improved for value added products. H1FY25 Financial Highlights: Revenue stood at Rs 1,285 crore, growth of 37% on account of volume growth from Derivative products. Revenue contribution from Derivatives & Specialty business increased to 56% in H1FY25 vs 42% in H1FY24. EBITDA stood at Rs 355 crore vs Rs 203 crore in H1FY24, grew by 75%. EBIDTA margin stood at 28% in H1FY25 vs 22% in H1FY24 on account of increase in utilization and volume contribution from new projects commissioned. PAT grew by 139% to Rs 166 crore. PAT margin grew to 13% vs 7% in H1FY24 H1FY25 Operational Highlights: Sales volume grew 17% YoY, it majorly comes from Derivatives and Specialty business. Capacity utilization stood at 83% in H1FY25 vs 74% in H1FY24. Realizations dropped for all the products in H1FY25 vs H1FY24 Maulik Patel; Chairman and Managing Director, Epigral said: “Epigral witnessed the topline growth of 37% in H1FY25, on account of 17% sales volume growth coming from high value products of Derivatives and Specialty business, despite marginal drop in realizations for all the products. Revenue contribution from Derivative and Specialty business has reached to 59% in Q2FY25 vs 46% in Q2FY24”. “At Epigral we are focused on continuous growth and entering products which are 1st time in India. In line with that, we had entered into CPVC and ECH, import substitute products. Considering the acceptance of our product, market size and growing demand for both the products, we are excited to further expand in both the products and double it from our existing capacity. The additional capacities are expected to get commissioned by H1Y27 and these projects are expected to contribute FY27 onwards. Our strategy to diversify into value added products, strengthening our integrated complex and sustained investment in capex will help us efficiency of scale and create value for our shareholders,” Result PDF